Phase II Study with Ifosfamide, Carboplatin, Etoposide (ICE Regimen) at Intermediate Dosage for Advanced Non Small Cell Lung Cancer (NSCLC)

P. Preti, G. Poggi, A. M. Cuomo, F. S. Robustelli Della Cuna, A. Zambelli, L. Pavesi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE regimen) along with mesna in 26 previously untreated patients with non small cell lung cancer (NSCLC). Thirteen stage III B and 13 stage IV patients received intermediate doses of ifosfamide (1000 mg/m2), carboplatin (120 mg/m2) and etoposide (120 mg/m2) given intravenously on day 1 to 3 every 4 weeks. Except for one patient who experienced grade 3 transient thrombocytopenia no major events of hematological or systemic toxicity were observed. Response rate (27%, 95% C.I., 10 to 44%), median duration of response (9 months, range 6-15), and survival (9.5 months, range 2-44+) were comparable to those achieved with conventional cisplatin-containing regimens. Our ICE combination, as compared to standard or high dose schedules appears effective, safe, well tolerated, and devoid of severe hematological toxicity.

Original languageEnglish
Pages (from-to)492-495
Number of pages4
JournalJournal of Chemotherapy
Volume10
Issue number6
Publication statusPublished - 1998

Fingerprint

Ifosfamide
Carboplatin
Etoposide
Non-Small Cell Lung Carcinoma
Mesna
Cisplatin
Appointments and Schedules
Survival

Keywords

  • Carboplatin
  • Etoposide
  • Ifosfamide
  • Lung cancer
  • Non small-cell lung cancer

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Cite this

Preti, P., Poggi, G., Cuomo, A. M., Robustelli Della Cuna, F. S., Zambelli, A., & Pavesi, L. (1998). Phase II Study with Ifosfamide, Carboplatin, Etoposide (ICE Regimen) at Intermediate Dosage for Advanced Non Small Cell Lung Cancer (NSCLC). Journal of Chemotherapy, 10(6), 492-495.

Phase II Study with Ifosfamide, Carboplatin, Etoposide (ICE Regimen) at Intermediate Dosage for Advanced Non Small Cell Lung Cancer (NSCLC). / Preti, P.; Poggi, G.; Cuomo, A. M.; Robustelli Della Cuna, F. S.; Zambelli, A.; Pavesi, L.

In: Journal of Chemotherapy, Vol. 10, No. 6, 1998, p. 492-495.

Research output: Contribution to journalArticle

Preti, P, Poggi, G, Cuomo, AM, Robustelli Della Cuna, FS, Zambelli, A & Pavesi, L 1998, 'Phase II Study with Ifosfamide, Carboplatin, Etoposide (ICE Regimen) at Intermediate Dosage for Advanced Non Small Cell Lung Cancer (NSCLC)', Journal of Chemotherapy, vol. 10, no. 6, pp. 492-495.
Preti, P. ; Poggi, G. ; Cuomo, A. M. ; Robustelli Della Cuna, F. S. ; Zambelli, A. ; Pavesi, L. / Phase II Study with Ifosfamide, Carboplatin, Etoposide (ICE Regimen) at Intermediate Dosage for Advanced Non Small Cell Lung Cancer (NSCLC). In: Journal of Chemotherapy. 1998 ; Vol. 10, No. 6. pp. 492-495.
@article{759eb979514e44a9a8ffd9e25e2b7cdf,
title = "Phase II Study with Ifosfamide, Carboplatin, Etoposide (ICE Regimen) at Intermediate Dosage for Advanced Non Small Cell Lung Cancer (NSCLC)",
abstract = "We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE regimen) along with mesna in 26 previously untreated patients with non small cell lung cancer (NSCLC). Thirteen stage III B and 13 stage IV patients received intermediate doses of ifosfamide (1000 mg/m2), carboplatin (120 mg/m2) and etoposide (120 mg/m2) given intravenously on day 1 to 3 every 4 weeks. Except for one patient who experienced grade 3 transient thrombocytopenia no major events of hematological or systemic toxicity were observed. Response rate (27{\%}, 95{\%} C.I., 10 to 44{\%}), median duration of response (9 months, range 6-15), and survival (9.5 months, range 2-44+) were comparable to those achieved with conventional cisplatin-containing regimens. Our ICE combination, as compared to standard or high dose schedules appears effective, safe, well tolerated, and devoid of severe hematological toxicity.",
keywords = "Carboplatin, Etoposide, Ifosfamide, Lung cancer, Non small-cell lung cancer",
author = "P. Preti and G. Poggi and Cuomo, {A. M.} and {Robustelli Della Cuna}, {F. S.} and A. Zambelli and L. Pavesi",
year = "1998",
language = "English",
volume = "10",
pages = "492--495",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "6",

}

TY - JOUR

T1 - Phase II Study with Ifosfamide, Carboplatin, Etoposide (ICE Regimen) at Intermediate Dosage for Advanced Non Small Cell Lung Cancer (NSCLC)

AU - Preti, P.

AU - Poggi, G.

AU - Cuomo, A. M.

AU - Robustelli Della Cuna, F. S.

AU - Zambelli, A.

AU - Pavesi, L.

PY - 1998

Y1 - 1998

N2 - We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE regimen) along with mesna in 26 previously untreated patients with non small cell lung cancer (NSCLC). Thirteen stage III B and 13 stage IV patients received intermediate doses of ifosfamide (1000 mg/m2), carboplatin (120 mg/m2) and etoposide (120 mg/m2) given intravenously on day 1 to 3 every 4 weeks. Except for one patient who experienced grade 3 transient thrombocytopenia no major events of hematological or systemic toxicity were observed. Response rate (27%, 95% C.I., 10 to 44%), median duration of response (9 months, range 6-15), and survival (9.5 months, range 2-44+) were comparable to those achieved with conventional cisplatin-containing regimens. Our ICE combination, as compared to standard or high dose schedules appears effective, safe, well tolerated, and devoid of severe hematological toxicity.

AB - We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE regimen) along with mesna in 26 previously untreated patients with non small cell lung cancer (NSCLC). Thirteen stage III B and 13 stage IV patients received intermediate doses of ifosfamide (1000 mg/m2), carboplatin (120 mg/m2) and etoposide (120 mg/m2) given intravenously on day 1 to 3 every 4 weeks. Except for one patient who experienced grade 3 transient thrombocytopenia no major events of hematological or systemic toxicity were observed. Response rate (27%, 95% C.I., 10 to 44%), median duration of response (9 months, range 6-15), and survival (9.5 months, range 2-44+) were comparable to those achieved with conventional cisplatin-containing regimens. Our ICE combination, as compared to standard or high dose schedules appears effective, safe, well tolerated, and devoid of severe hematological toxicity.

KW - Carboplatin

KW - Etoposide

KW - Ifosfamide

KW - Lung cancer

KW - Non small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0032237908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032237908&partnerID=8YFLogxK

M3 - Article

C2 - 9876059

AN - SCOPUS:0032237908

VL - 10

SP - 492

EP - 495

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 6

ER -